



# EXPRES<sup>2</sup>ION

BIOTECHNOLOGIES

Half Year Report 2018 (Q2)

2018-01-01 – 2018-06-30

ExpreS<sup>2</sup>ion Biotech Holding AB

559033-3729

**DISCLAIMER:**

**THIS IS A NON-CERTIFIED TRANSLATION OF THE  
SWEDISH ORIGINAL DOCUMENT, WHICH PREVAILS**

## Conclusion of the Half Year Report 2018

*“Expres<sup>2</sup>ion Biotech Holding AB” refers to Expres<sup>2</sup>ion Biotech Holding AB with corporate identity number 559033-3729. The Company” or “Expres<sup>2</sup>ion” refers to the group, i.e. Expres<sup>2</sup>ion Biotech Holding AB and its fully owned operational subsidiary Expres<sup>2</sup>ion Biotechnologies ApS, Denmark.*

### Second quarter (2018-04-01 to 2018-06-30)

- Group turnover amounted to 2,982 (2,310)\* KSEK
- Result after financial items amounted to -4,101 (-3,097) KSEK
- Net income amounted to -3,322 (-2,636) KSEK
- Net income per share\*\* amounted to -0,28 (-0,30) SEK

### First half year (2018-01-01 to 2018-06-30)

- Group turnover amounted to 5,260 (5,924)\* KSEK
- Result after financial items amounted to -7,552 (-4,315) KSEK
- Net income amounted to -6,539 (-3,745) KSEK
- Net income per share\*\* amounted to -0.59 (-0.43) SEK
- Cash flow from operating activities amounted to -6,513 (-4,981) KSEK
- Equity ratio\*\*\* amounted to 62.0 (46.4) %
- Cash and cash equivalents amounted to 12,219 (1,465) KSEK

*\*Numbers in parenthesis are the numbers from the same period in 2017.*

*\*\*The Group’s net income per share: the net income for the period divided by 11,073,682, which is the average number of shares for the whole period. The average number of shares for the second quarter was 12,002,015. The total number of shares in Expres<sup>2</sup>ion Biotech Holding AB was 12,002,015 shares per 2018-06-30.*

*\*\*\*Equity ratio: Shareholder’s equity divided by total capital.*

### Significant events during the second quarter of 2018

- On April 20, Expres<sup>2</sup>ion Biotech Holding AB announced that its subsidiary’s U.S.-based partner and licensee Integrated BioTherapeutics, Inc. (“IBT”) has initiated sales and marketing of its first Expres<sup>2</sup>-based product. It was also stated that IBT is planning to launch approximately five products for research purposes annually, and that the collaboration is expected to generate annual revenues of up to 1 MSEK for Expres<sup>2</sup>ion, when fully implemented.
- On May 3, Expres<sup>2</sup>ion published its annual report for 2017. The annual report is available on Expres<sup>2</sup>ion’s website ([www.expres2ionbio.com](http://www.expres2ionbio.com)).
- On May 17, Expres<sup>2</sup>ion announced that the Company’s patent application “Improved Protein Expression System”, that covers the entire Expres<sup>2</sup> platform, has been approved in Canada.
- On May 24th, the annual general meeting of Expres<sup>2</sup>ion Biotech Holding AB (publ) was held. The report is available on the Company’s website ([www.expres2ionbio.com](http://www.expres2ionbio.com)).
- On May 29, the Company announced a collaboration agreement with Genlbet Biopharmaceuticals S.A. regarding vaccine development and GMP manufacturing. The Board’s assessment is that the agreement strengthens Expres<sup>2</sup>ion’s position as a full-service provider from discovery up to early clinical development.
- On June 15, Expres<sup>2</sup>ion announced that the Company will present its malaria and breast cancer vaccine research at two scientific events in June 2018.

### Significant events after the end of the period

- None.

## A word from our CEO, Dr. Steen Klysner

With the first half of 2018 behind us, time has come for me to summarise the second quarter that again had several exciting news items to offer.

**Financial results:** We continue to see positive revenue development based on sales and services relating to our core ExpreS<sup>2</sup> platform. Due to the nature of our business model, revenues are however unevenly distributed over the year, and we experience large quarterly variations. An example is the record high Q1 2017, where one significant customer project resulted in the highest total turnover so far and thereby even exceeding the turnover in Q1 2018. Having said that, the overall trend is still positive, and we have now identified and hired the additional marketing and technical personnel that is required to step up our business activities on all fronts.



Following the period Bent U. Frandsen, former Vice President of Business Development, was appointed CBO (Chief Business Officer) and will be in charge of our efforts to substantially increase our customer base. Additionally, the IR communication agency Honeybadger was appointed as the Company's non-exclusive IR partner to handle an increased market communication going forward.

The added personnel, investments in new technology and the acceleration of AdaptVac's Her-2 breast cancer project (AV001) that is deemed to be of high value, has inevitably increased our running costs during the quarter. We do, however, expect these investments to translate into increased revenues in the following quarters. More importantly, we expect these efforts also to add to a significant value generation and consequently create extensive long-term revenues from AdaptVac assets and other projects with potential high value creation.

**Core business:** The quarter started strongly as our American partner and licensee, Integrated BioTherapeutics, announced the launch of their first ExpreS<sup>2</sup>-based product. The product, an Ebola virus glycoprotein, is the first of several planned ExpreS<sup>2</sup>-based products that will be included in IBT's portfolio of high quality biological tools for the development of diagnostic and therapeutic products. An additional product was launched later in the quarter, and we have now started to see revenues coming in. Furthermore, we expect this to open up additional business opportunities for ExpreS<sup>2</sup>ion.

In May, we announced the initiation of a strategic collaboration with Genlbet Biopharmaceuticals, a new Portuguese partner. Genlbet is an experienced and recognised player in vaccine development and GMP manufacturing, and the agreement thus adds further strength to ExpreS<sup>2</sup>ion's position as a full-service provider and vaccine developer.

At the end of June, our scientists presented the ExpreS<sup>2</sup> platform in relation to data from the malaria and breast cancer vaccine development projects at two international conferences in Oxford, UK and Quebec, Canada respectively. Scientific events like these are great platforms to demonstrate our position in the lead of vaccine development. In addition, a scientific article documenting successful use of our platform for regulated production of material for clinical studies, was published in a recognised journal after the end of the period. I am delighted to note, that we as a consequence, experience a great deal of interest in our work from both the scientific community and biopharmaceutical companies.

**Patents:** Canada was mentioned twice in our news feed for the second quarter, as our core platform patent "Improved Protein Expression System" was approved by the Canadian Patent Office. This approval was a special occasion, as it is the final piece of the desired patent protection for our core technology platform. It is now protected in all major and upcoming markets, which is of fundamental importance for players in the global vaccine market that we operate in.

**External Projects:** We are still awaiting the results from the blood stage malaria phase 2a clinical trials at the Oxford Jenner Institute and the PAMVAC consortium's placental malaria phase 1a/1b trial, where the clinical part has been concluded. It is important to note that the analysis and reporting part of multi-centre and -partner studies like these are always time consuming. With that said, we are of course eager to see the final results when they become public.

**AdaptVac:** The activities in our joint venture AdaptVac is progressing at high speed, and I am pleased to note that the new organisation and collaboration is working well. With respect to the internal development and projects in this high value, highly competitive market, we unfortunately need to be scarce with information. We do, however, expect to be able to communicate on some of the progress in the coming quarters. Presently, I can just add that the combination of AdaptVac's VLP technology and the ExpreS<sup>2</sup> platform has already attracted interest from new customers and potential business projects for ExpreS<sup>2</sup>ion.

In conclusion, the Company has continued to make progress during the second quarter of 2018, with the much-appreciated support of our partners and shareholders. We look forward to continuing this development, as well as to pursue new, upcoming opportunities in the future.

**Dr. Steen Klysner**  
CEO, ExpreS<sup>2</sup>ion Biotech Holding AB

## About ExpreS<sup>2</sup>ion Biotech Holding AB

A key part in the development of modern biopharmaceuticals is the complex proteins that constitutes the active substance. These proteins are produced using technology platforms based on genetic modification of cells. This method is for instance used when developing human insulin, antibodies and a large number of new vaccines. However, these proteins are difficult to develop and produce in a safe and cost-effective manner, as well as with the level of quality required by authorities for use in human medicine.

The operating subsidiary, ExpreS<sup>2</sup>ion Biotechnologies ApS, was established in 2010 as a spinout from the Danish pharmaceutical company Affitech A/S. The Company was founded by the doctors Charlotte Dyring, Wian de Jongh and Martin Roland Jensen, with the business idea to provide proteins to research institutions and vaccine producing companies using a new platform technology. Although the Company's platform technology is constantly in development, it is currently a complete commercialised product. Since the Company was founded, the platform has been a part in the development of over 250 different proteins and used by or for almost one hundred different clients and partners, such as Hoffman La-Roche and Novartis Pharma.

### The ExpreS<sup>2</sup> platform

The Company's operations are based on the patent protected ExpreS<sup>2</sup> platform and its ability to produce complex proteins. The main component of the ExpreS<sup>2</sup> platform is S2 cells that can produce proteins, as well as the Company's patented expression vectors that are the part of the platform that, among other things, makes it possible for the cells to generate a high yield. The platform has a number of features that, according to the Board's assessment, distinguish it from competing technologies:

- It has on occasion been the only known method for producing specific proteins.
- It is significantly less costly and time-consuming than alternative methods, which is an important competitive advantage, considering for example time-to-market and patent validity, but it also makes the platform particularly valuable in the development of diagnostics and vaccines for infectious and rapidly growing pandemics.
- The method generates a significantly higher yield, i.e. amount of protein per manufacturing batch, compared to competing systems.
- The method provides very homogeneous manufacturing batches, which is a requirement in pharmaceutical development.

### Business model and market potential

ExpreS<sup>2</sup>ion Biotechnologies' business model is structured in a way that allows the Company to not only market licenses to use the ExpreS<sup>2</sup> platform as a whole, but also parts of it, thus allowing the client to participate in or be entirely responsible for the development of the required proteins. The Company can also sell reagents and kits, including diagnostics. The Company may also charge clients for the production and delivery of proteins as finished products, using the ExpreS<sup>2</sup> platform. The Company has two main categories of clients; pharmaceutical companies and research institutions. The Company can address both types of organisations since the ExpreS<sup>2</sup> platform can be adapted to both basic academic research and commercial drug development. The Company's clients are not limited to any geographic area and are located in several different parts of the world. The Company's overall objective for the ExpreS<sup>2</sup> platform is to consolidate it as a preferred method for protein production within research and development of vaccines and immunotherapy, as well as utilising the platform for the development of its own and partly owned products. ExpreS<sup>2</sup>ion Biotechnologies is to be the obvious partner when clients or partners need rapid development and advanced proteins during the process of developing new vaccines and immunotherapy. In addition, the Company is actively working with developing new products within its core technology, as well as to identify and include new valuable technology platforms and products with synergy effects to ExpreS<sup>2</sup>ion 's platform.

The market potential for ExpreS<sup>2</sup>ion is difficult to estimate, but according to the Board's assessment, it is very large. The treatment for malaria for example, had a global economic value of USD 2.7 billion in 2013<sup>1</sup>. The total global vaccine market is growing, and it is estimated to reach a total value of approximately USD 58 billion in 2019<sup>2</sup> from being valued at around USD 30 billion.

<sup>1</sup> [http://www.who.int/malaria/publications/world\\_malaria\\_report\\_2014/wmr-2014-no-profiles.pdf](http://www.who.int/malaria/publications/world_malaria_report_2014/wmr-2014-no-profiles.pdf)

<sup>2</sup> <https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html>

In addition to ExpreS<sup>2</sup>ion's core business activities described above, the Company initiated the Joint Venture AdaptVac ApS ("AdaptVac") in 2017 together with NextGen Vaccines ApS ("NextGen"), a company established by researchers from the University of Copenhagen. AdaptVac has a worldwide exclusive license to a new Plug-and-Play Virus Like Particle (VLP) technology, which enables accelerated development of efficient therapeutic and prophylactic vaccines within high value market segments in oncology, infectious diseases and immunological diseases. The aim of AdaptVac is to establish a world class company for the development of competitive vaccines and therapeutic treatments in this segment. The combination of ExpreS<sup>2</sup>ion's technology and know-how and NextGen's unique expertise within the VLP technology has the potential to create a robust and versatile company within the field of new vaccines and immunotherapies. With AdaptVac, ExpreS<sup>2</sup>ion also enters the market for Immuno-Oncology which, according to Research and Markets 2018, is estimated to surpass a market value of USD 100 billion by 2022.

### Company structure and shareholding

ExpreS<sup>2</sup>ion Biotech Holding AB has a fully owned subsidiary, ExpreS<sup>2</sup>ion Biotechnologies ApS, Denmark. All operational activity takes place in the subsidiary, and ExpreS<sup>2</sup>ion Biotech Holding AB's only operational activity is to own the subsidiary ExpreS<sup>2</sup>ion Biotechnologies ApS. In addition to this, ExpreS<sup>2</sup>ion Biotechnologies ApS owns 50 percent of the shares in AdaptVac ApS, Denmark. This company is accounted for as a jointly governed company. In addition to the above, the Company does not own any shares in other companies.

### Developments in figures for Q2 2018

#### Turnover

Group turnover during the second quarter 2018 amounted to KSEK 2,982 (2,310). Revenues comes mainly from the development and production of reagents to customers. The revenue has increased significantly compared to the latest two quarters and the revenue in Q2-18 alone is approximately 29% higher compared with the same period last year. Revenue for the first six months has however decreased compared to the same period in 2017, due to the exceptional high revenues in Q1 2017 which reflected a very significant amount of work related to one customer project.

#### Result

Consolidated net result for the second quarter of 2018 amounted to KSEK -3,322 (-2,636). The increase in sales activities since 2016 has had a positive impact on the Company's turnover, but the net result however also reflects increased costs attributable to an increased activity level.

#### Cash and cash equivalents

As of June 30, 2018, ExpreS<sup>2</sup>ion's cash and cash equivalents amounted to KSEK 12,219 (1,464), which reflects the share emission that was executed in March 2018.

### Shareholder structure

The table below lists all shareholders who held more than 5% of the capital and voting shares in ExpreS<sup>2</sup>ion Biotech Holding AB as of June 30th, 2018.

Name	Number of shares held	Share of votes and capital
ExpreS <sup>2</sup> ion Holding ApS <sup>1</sup>	1,744,370	14.53%
AR Consult ApS <sup>2</sup>	1,328,376	11.07%
Försäkringsbolaget, Avanza Pension	1,052,591	8.77 %
Ericsson, Anders	699,411	5.83%
Summary shareholders over 5 %	4,824,748	40.20 %
Remaining shareholders (below 5 %)	7,177,267	59.80 %
<b>Total 30/06/2018</b>	<b>12,002,015</b>	<b>100.00%</b>

- <sup>1</sup>Chairman of the board Martin Roland Jensen holds 32.22% of the voting and capital shares in ExpreS<sup>2</sup>ion Holding ApS. COO Charlotte Dyring owns 39.23% of the voting and capital shares in ExpreS<sup>2</sup>ion Holding ApS. CSO Wian de Jongh owns 28.55% of the voting and capital shares in ExpreS<sup>2</sup>ion Holding ApS.
- <sup>2</sup>Board member Allan Rosetzky owns 100% of the shares in AR Consult ApS.

### The share

ExpreS<sup>2</sup>ion Biotech Holding AB's share was listed at Nasdaq Stockholm First North on July 29, 2016. The trading name of the share is EXPRS2 and the ISIN-code is SE0008348262. As of January 1, 2018, the number of shares in ExpreS<sup>2</sup>ion Biotech Holding AB amounted to 9,601,612. As of June 30, 2018, the number of shares in ExpreS<sup>2</sup>ion Biotech Holding AB amounted to 12,002,015. The average amount of shares in the second quarter of 2018 amounted to 12,005,015. There is one single class of shares in the Company. All shares carry equal rights to a share of the Company's assets and earnings.

### Operational risks and uncertainties

The risks and uncertainties that ExpreS<sup>2</sup>ion's operations are exposed to are summarised in terms of pharmaceutical development, competition, technology development, patents, government requirements, capital requirements, currencies and interest rates. During the current period, no significant changes regarding risk or uncertainty factors have occurred. For more detailed reporting of risks and uncertainties, refer to the previously published memorandum, published in February 2018, and the Company's annual report for the fiscal year of 2017.

### Auditor review

This interim report has not been formally reviewed by the Company's auditor.

### Accounting principles

ExpreS<sup>2</sup>ion Biotech Holding AB applies the Swedish Annual Accounts Act and Swedish Accounting Standards Board's general standard BFNAR 2012:1 when preparing the financial statements.

### Financial calendar

Interim report 3, 2018	22/11/2018
Year-end report, 2018	28/02/2019

### Certified Adviser

Sedermersa Fondkommission is appointed as the Certified Adviser of ExpreS<sup>2</sup>ion Biotech Holding AB.

### For more information, please contact

Dr. Steen Klysner, CEO  
 Telephone: +45 2062 9908  
 Email: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

*The Board of Directors and the CEO indicates that the Half Year report presents a fair view of ExpreS<sup>2</sup>ion Biotech Holding AB's business.*

Hørsholm, August 24, 2018  
 ExpreS<sup>2</sup>ion Biotech Holding AB  
 c/o Mazars SET, Terminalgatan 1, 252 24 Helsingborg, Sweden

*Board of Directors and CEO*

## Financial overview

### Income statement in brief – group

KSEK	2018-04-01	2017-04-01	2018-01-01	2017-01-01	2017-01-01
	2018-06-30	2017-06-30	2018-06-30	2017-06-30	2017-12-31
	3 months	3 months	6 months	6 months	12 months
Net sales	2,982	2,310	5,260	5,924	9,795
Raw materials and consumables	- 857	- 583	- 1,529	- 1 131	- 2 193
<b>Gross earnings</b>	<b>2,125</b>	<b>1,727</b>	<b>3,731</b>	<b>4,793</b>	<b>7,602</b>
Other external costs	- 2,160	- 1,722	- 4,013	- 2,989	- 5,928
Personnel costs	- 3,339	- 2,421	- 5,973	- 4,758	- 10,319
Result in jointly governed companies	0	0	0	0	- 509
<b>Operating profit/loss before depreciation</b>	<b>- 3,374</b>	<b>- 2,416</b>	<b>- 6,255</b>	<b>- 2,954</b>	<b>- 9,154</b>
Depreciation	- 662	- 568	- 1,261	- 1,127	- 2,281
<b>Operating profit/loss</b>	<b>- 4,036</b>	<b>- 2,984</b>	<b>- 7,516</b>	<b>- 4,081</b>	<b>- 11,435</b>
Other financial income	62	0	210	0	146
Other financial costs	- 127	- 113	- 246	- 234	- 461
<b>Profit/loss from financial items</b>	<b>- 65</b>	<b>- 113</b>	<b>- 36</b>	<b>- 234</b>	<b>- 315</b>
<b>Profit/loss after financial items</b>	<b>- 4,101</b>	<b>- 3,097</b>	<b>- 7,552</b>	<b>- 4,315</b>	<b>- 11,750</b>
Tax	779	461	1,013	570	1,915
<b>Net profit/loss for the year</b>	<b>- 3,322</b>	<b>- 2,636</b>	<b>- 6,539</b>	<b>- 3,745</b>	<b>- 9,835</b>

**Balance sheet in brief – group**

<b>KSEK</b>	<b>2018-06-30</b>	<b>2017-06-30</b>	<b>2017-12-31</b>
<b>Assets</b>			
Concessions, patents, licenses, trademarks and similar intellectual rights			
Goodwill	7,929	8,834	8,241
<b>Total intangible fixed assets</b>	<b>1,706</b>	<b>2,148</b>	<b>1,900</b>
	<b>9,635</b>	<b>10,982</b>	<b>10,141</b>
Other tangible assets			
<b>Total tangible assets</b>	<b>1,007</b>	<b>558</b>	<b>632</b>
	<b>1,007</b>	<b>558</b>	<b>632</b>
Interest in group companies			
Other long-term receivables	0	33	0
<b>Financial assets</b>	<b>436</b>	<b>287</b>	<b>408</b>
	<b>436</b>	<b>320</b>	<b>408</b>
<b>Total fixed assets</b>			
	<b>11,078</b>	<b>11,860</b>	<b>11,181</b>
Accounts receivable			
Tax receivables	765	1,647	1,086
Other receivables	2,433	1,926	1,478
Receivables from group companies	2,179	2,907	1,331
Prepaid expenses	849	0	315
<b>Total receivables</b>	<b>246</b>	<b>99</b>	<b>336</b>
Cash and cash equivalents	<b>6,472</b>	<b>6,579</b>	<b>4,546</b>
<b>Total current assets</b>	<b>12,219</b>	<b>1,464</b>	<b>1,508</b>
	<b>18,691</b>	<b>8,043</b>	<b>6,054</b>
<b>TOTAL ASSETS</b>	<b>29,769</b>	<b>19,903</b>	<b>17,235</b>
<b>Equity and liabilities</b>			
Share capital	1,334	970	1,067
Other capital contributions	41,806	20,307	23,815
Other equity including net profit for the period	-24,694	-12,045	-18,145
<b>Total equity</b>	<b>18,446</b>	<b>9,232</b>	<b>6,737</b>
Accrued tax liabilities	1,744	2,318	1,813
<b>Total liabilities</b>	<b>1,744</b>	<b>2,318</b>	<b>1,813</b>
Other long-term liabilities	6,778	5,099	6,324
<b>Total long-term liabilities</b>	<b>6,778</b>	<b>5,099</b>	<b>6,324</b>
Liabilities to credit institutions	411	1,051	75
Accounts payable	591	554	470
Other liabilities	1,799	1,649	1,816
<b>Total contingent liabilities</b>	<b>2,801</b>	<b>3,254</b>	<b>2,361</b>
<b>Total liabilities</b>	<b>11,323</b>	<b>10,671</b>	<b>10,498</b>
<b>TOTAL SHAREHOLDER EQUITY AND LIABILITIES</b>	<b>29,769</b>	<b>19,903</b>	<b>17,235</b>



Cash flow statement in brief – group

KSEK	2018-04-01	2017-04-01	2018-01-01	2017-01-01	2017-01-01
	2018-06-30	2018-06-30	2018-06-30	2017-06-30	2017-12-31
	3 months	3 months	6 months	6 months	12 months
Operating profit	- 4,036	- 2,985	- 7,516	- 4,082	- 11,435
Adjustments for depreciation	662	568	1,261	1,127	2,281
Received interest	0	0	0	0	91
Interest paid	- 141	- 137	- 254	- 243	- 581
Company tax paid	- 2	- 4	- 4	- 22	1,262
<b>Cash flow from operating activities before changes in working capital</b>	<b>- 3,517</b>	<b>- 2,558</b>	<b>- 6,513</b>	<b>- 3,220</b>	<b>- 8,382</b>
Decrease / increase of current receivables	- 348	1,665	- 293	- 370	1,446
Decrease / increase of current liabilities	- 1,467	- 116	- 512	- 1,406	- 1,672
<b>Cash flow from operating activities</b>	<b>- 5,332</b>	<b>- 1,009</b>	<b>- 7,318</b>	<b>- 4,996</b>	<b>- 8,608</b>
Investments in tangible fixed assets	- 533	0	- 533	0	- 206
<b>Cash flow from investing activities</b>	<b>- 533</b>	<b>0</b>	<b>- 533</b>	<b>0</b>	<b>- 206</b>
Leasing agreement	458	0	427	211	380
Redemption of options	0	0	58	0	79
Issuance of new shares	0	0	19,203	0	3,928
Costs of issuing shares	0	0	- 1,003	0	- 402
<b>Cash flow from financing activities</b>	<b>458</b>	<b>0</b>	<b>18,685</b>	<b>211</b>	<b>3,985</b>
<b>Cash flow for the period</b>	<b>-5,407</b>	<b>- 1,009</b>	<b>10,834</b>	<b>- 4,785</b>	<b>- 4,829</b>
Cash and cash equivalents at the beginning of the period	17,775	2,460	1,508	6,236	6,236
Exchange difference cash and cash equivalents	- 149	0	- 123	0	101
<b>Cash and cash equivalents at the end of the period</b>	<b>12,219</b>	<b>1,451</b>	<b>12,219</b>	<b>1,451</b>	<b>1,508</b>

Changes in equity in brief – group

KSEK	2018-04-01	2017-04-01	2018-01-01	2017-01-01	2017-01-01
	2018-06-30 3 months	2017-06-30 3 months	2018-06-30 6 months	2017-06-30 6 months	2017-12-31 12 months
Total equity at the beginning of the period	21,836	11,784	6,737	12,880	12,880
Issuance of new shares	0	0	19,203	0	3,928
Redemption of options	0	0	58	0	79
Issuing cost	0	0	- 1,003	0	- 402
Profit/loss for the period	- 3,322	- 2,636	- 6,539	- 3,745	- 9,835
Exchange difference	- 68	84	- 10	97	87
<b>Total equity at the end of the period</b>	<b>18,446</b>	<b>9,232</b>	<b>18,446</b>	<b>9,232</b>	<b>6,737</b>

Income statement in brief – parent company

KSEK	2018-04-01	2017-04-01	2018-01-01	2017-01-01	2017-01-01
	2018-06-30	2017-06-30	2018-06-30	2017-06-30	2017-12-31
	3 months	3 months	6 months	6 months	12 months
Net sales	89	0	89	0	305
Other external costs	- 797	- 346	- 1 388	- 566	- 1,859
Personnel costs	- 188	- 117	- 227	- 117	- 234
<b>Operating profit/loss before depreciation</b>	<b>- 896</b>	<b>- 463</b>	<b>- 1 526</b>	<b>- 683</b>	<b>- 1,788</b>
Depreciation	0	0	0	0	0
<b>Operating profit/loss</b>	<b>- 896</b>	<b>- 463</b>	<b>- 1 526</b>	<b>- 683</b>	<b>- 1,788</b>
Other financial income	179	7	230	7	81
Other financial costs	0	- 1	0	- 7	- 3
<b>Result from financial investments</b>	<b>179</b>	<b>6</b>	<b>230</b>	<b>0</b>	<b>78</b>
<b>Pre-tax profit</b>	<b>- 717</b>	<b>- 457</b>	<b>- 1 296</b>	<b>- 683</b>	<b>- 1,710</b>
Tax	0	0	0	0	0
<b>Net profit/loss for the period</b>	<b>- 717</b>	<b>- 457</b>	<b>- 1 296</b>	<b>- 683</b>	<b>- 1,710</b>

Balance sheet in brief – parent company

KSEK	2018-06-30	2017-06-30	2017-12-31
<b>Assets</b>			
Deposits	50	50	50
Shares in group companies	17,496	17,496	17,496
Receivables from group companies	15,999	1,343	4,099
<b>Total financial fixed assets</b>	<b>33,545</b>	<b>18,889</b>	<b>21,645</b>
<b>Total fixed assets</b>	<b>33,545</b>	<b>18,889</b>	<b>21,645</b>
Tax receivables	21	36	15
Other receivables	91	197	202
Prepaid expenses	0	0	71
<b>Total current receivables</b>	<b>112</b>	<b>233</b>	<b>288</b>
Cash and cash equivalents	5,637	533	214
<b>Total current assets</b>	<b>5,749</b>	<b>766</b>	<b>502</b>
<b>TOTAL ASSETS</b>	<b>39,294</b>	<b>19,655</b>	<b>22,147</b>
<b>Equity and liabilities</b>			
Share capital	1,334	970	1,067
Share premium account	38,929	20,306	22,645
Net profit/loss for the period	- 1 296	- 1,850	- 1,710
<b>Total equity</b>	<b>38 967</b>	<b>19,426</b>	<b>22,002</b>
Other liabilities	327	229	145
<b>Total contingent liabilities</b>	<b>327</b>	<b>229</b>	<b>145</b>
<b>Total liabilities</b>	<b>327</b>	<b>229</b>	<b>145</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>39,294</b>	<b>19,655</b>	<b>22,147</b>

Cash flow statement in brief – parent company

KSEK	2018-04-01	2017-04-01	2018-01-01	2017-01-01	2017-01-01
	2018-06-30	2017-06-30	2018-06-30	2017-06-30	2017-12-31
	3 months	3 months	6 months	6 months	12 months
Operating profit	- 900	- 463	- 1,530	- 683	- 1,788
Received interest	0	7	0	7	0
Interest paid	- 1	- 13	- 2	- 15	- 5
Company tax paid	- 2	- 4	- 4	- 22	3
<b>Cash flow from operating activities before changes in working capital</b>	<b>- 903</b>	<b>- 473</b>	<b>- 1,536</b>	<b>- 713</b>	<b>- 1,790</b>
Decrease / increase of current receivables	12	- 40	182	- 58	- 134
Decrease / increase of current liabilities	187	88	187	- 217	- 308
<b>Cash flow from operating activities</b>	<b>- 704</b>	<b>- 425</b>	<b>- 1,167</b>	<b>- 988</b>	<b>- 2,232</b>
Loans group Company	- 10,721	- 1,434	- 11,668	- 1,290	- 3,971
<b>Cash flow from investing activities</b>	<b>- 10,721</b>	<b>- 1,434</b>	<b>- 11,668</b>	<b>- 1,290</b>	<b>- 3,971</b>
Issuance of new shares	0	0	19,203	0	3,928
Redemption of options	0	0	58	0	79
Costs of issuing shares	0	0	- 1,003	0	- 402
<b>Cash flow from financing activities</b>	<b>0</b>	<b>0</b>	<b>18,258</b>	<b>0</b>	<b>3,605</b>
<b>Cash flow for the period</b>	<b>11,425</b>	<b>- 1,859</b>	<b>5,423</b>	<b>- 2,278</b>	<b>- 2,598</b>
Cash and cash equivalents at the beginning of the period	17,062	2,393	214	2,812	2,812
<b>Cash and cash equivalents at the end of the period</b>	<b>5,637</b>	<b>534</b>	<b>5,637</b>	<b>534</b>	<b>214</b>

Changes in equity – parent company

KSEK	2018-04-01	2017-04-01	2018-01-01	2017-01-01	2017-01-01
	2018-06-30	2017-06-30	2018-06-30	2017-06-30	2017-12-31
	3 months	3 months	6 months	6 months	12 months
Total equity at the beginning of the period	39,681	19,882	22,002	20,107	20,107
Issuance of new shares	0	0	19,203	0	3,928
Redemption of options	0	0	58	0	79
Issuing expenses	0	0	- 1,003	0	- 402
Net profit/loss for the period	- 717	- 457	- 1 296	- 683	- 1,710
<b>Total equity at the end of the period</b>	<b>38,964</b>	<b>19,426</b>	<b>38,964</b>	<b>19,426</b>	<b>22,002</b>



# EXPRES<sup>2</sup>ION

BIOTECHNOLOGIES

Agern Allé 1, DK-2970 Hørsholm, Denmark  
[www.expreS2ionbio.com](http://www.expreS2ionbio.com)